Monitoring anticoagulants in the catheterization laboratory and in the ICU when using combination therapies

Debabrata Mukherjee, David J. Moliterno

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


The availability of potent antiplatelet, antithrombin, and fibrinolytic therapies for the treatment of acute coronary syndromes (ACS) and during percutaneous coronary interventions (PCI) has made monitoring these therapies an important issue. The use of these agents in combination has led to improved antithrombotic efficacy, albeit at the cost of higher bleeding in some situations. Current and evolving technologies to monitor the extent of inhibition of platelet aggregation and activity of antithrombotic agents when used as combination therapy will be covered in this overview. Table 1 lists various scenarios in which the monitoring of combination therapies may be useful. The clinically important question to be considered is whether the results generated from monitoring will effect a change that will improve efficacy (prevent thrombotic events) or reduce adverse events (bleeding) from these therapies. Since novel and increasingly potent agents continue to be developed, monitoring anticoagulation will continue to be of special interest.

Original languageEnglish
Title of host publicationClinical, Interventional and Investigational Thrombocardiology
Number of pages18
ISBN (Electronic)9780849344954
StatePublished - Jan 1 2005

Bibliographical note

Publisher Copyright:
© 2005 by Taylor & Francis Group, LLC.

ASJC Scopus subject areas

  • Medicine (all)
  • Pharmacology, Toxicology and Pharmaceutics (all)


Dive into the research topics of 'Monitoring anticoagulants in the catheterization laboratory and in the ICU when using combination therapies'. Together they form a unique fingerprint.

Cite this